GlassScriptPhysician profile
Harold Leach
NPI 1437144045
$4,260.87
in general payments reported to CMS, 2019-2025
34 companies · $582 in 2025
The $582 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $370 · 2021: $617 · 2022: $836 · 2023: $573 · 2024: $605 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $871.92 | 2019-2024 | |
| Hologic Sales and Service, LLC | $455.63 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Amgen INC. | $351.06 | 2019-2024 | Prolia, Evenity |
| Mayne Pharma Commercial LLC | $292.30 | 2021-2025 | |
| Daiichi Sankyo INC. | $248.94 | 2019-2024 | Injectafer |
| Astellas Pharma US INC | $247.90 | 2023-2025 | Veozah |
| Organon LLC | $178.86 | 2021-2024 | Nexplanon |
| Therapeuticsmd, INC. | $161.71 | 2019-2022 | |
| Medtronic, INC. | $159.65 | 2025 | Truclear |
| Coopersurgical, INC. | $134.56 | 2021-2024 | Paragard T 380a, Paragard T 380a, Endosee |
| Myovant Sciences INC. | $121.58 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $111.79 | 2019 | |
| Sumitomo Pharma America, INC. | $97.49 | 2023-2025 | Myfembree |
| Mylan Pharmaceuticals INC. | $85.76 | 2019-2022 | |
| Exeltis, USA INC. | $75.56 | 2020-2023 | Slynd |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.19 | 2021-2024 | |
| Shield Therapeutics INC | $71.85 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.38 | 2019-2022 | |
| Allergan, INC. | $61.49 | 2019-2020 | |
| Aspira Women'S Health INC | $54.35 | 2021-2022 | |
| Sage Therapeutics, LLC | $53.96 | 2024-2025 | Zurzuvae |
| Ascend Therapeutics US, LLC | $49.06 | 2021-2022 | |
| Evofem Biosciences, INC. | $33.03 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $29.82 | 2019-2020 | |
| Lupin INC. | $27.35 | 2019-2020 | |
| Avion Pharmaceuticals | $26.43 | 2019-2020 | |
| Exact Sciences Corporation | $22.74 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $16.77 | 2019 | |
| Mission Pharmacal Company | $16.66 | 2020 | |
| Millicent US INC | $16.11 | 2024 | Intrarosa, Femring |
| Scynexis, INC. | $15.18 | 2022 | |
| Meditrina | $14.32 | 2024 | |
| Amag Pharmaceuticals, INC. | $13.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Leach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.